

# PROGRAMME

LEIPZIG  
INTERVENTIONAL  
COURSE

L I N C

Konstantinos Donas

Page 1/2

Thursday, January 28, 2021

## MAIN ARENA 1

- 16:15 – 18:00** **Current concepts, innovations, and open questions in EVAR of complex infrarenal aortoiliac aneurysms**  
*MODERATOR:*  
Giovanni Torsello  
Frank Veith  
*PANEL:*  
Armando Lobato  
Eric Verhoeven  
**Konstantinos Donas**
- 16:15 – 16:40 Live case transmission from Paris  
Hôpital Marie Lannelongue Paris - Live case center
- 16:40 – 16:45 Best practices and technical learning on the on-label treatment of challenging necks: The EXCeL registry  
Marc van Sambeek
- 16:45 – 16:50 Contemporary options for treating juxtarenal aneurysm when infrarenal sealing is not enough  
**Konstantinos Donas**
- 16:50 – 16:55 EndoAnchors can facilitate and maintain successful standard EVAR for AAAs with challenging proximal necks  
Luis Mariano Ferreira
- 16:55 – 17:00 FEVAR technique – a case presentation  
Eric Ducasse
- 17:00 – 17:05 4xFEVAR: is it always needed to stent the celiac artery?  
Eric Verhoeven
- 17:05 – 17:10 Data on the 3 year clinical results of BeGraft in FEVAR  
Stéphan Haulon
- 17:10 – 17:15 Insight in the German FEVAR approval study to get bridging stents approved for the indication  
Eric Verhoeven
- 17:15 – 17:20 WeFlow-JAAA™: a new uncusomized device for juxtarenal AAA  
Wei Guo

**We are asking all faculty members to strictly respect the given time limits.**

# PROGRAMME

LEIPZIG  
INTERVENTIONAL  
COURSE

L I N C



Konstantinos Donas

Page 2/2

## Thursday, January 28, 2021

- |               |   |
|---------------|---|
| 17:20 – 17:25 | Type II endoleak and aortic aneurysm sac shrinkage after pre-emptive embolization of aneurysm sac side branches<br>Daniela Branzan                  |
| 17:25 – 17:40 | Live case transmission from Leipzig<br>Universitätsklinikum Leipzig, Abt. Angiologie - Live case center   |
| 17:40 – 17:45 | How stent graft design influences overall AAA sac dynamics and overall therapy success<br>Ross Milner   |
| 17:45 – 17:50 | EVAR long term perspectives: facts and figures from the GREAT registry experience at 5 years<br>Chandler Long                                       |
| 17:50 – 17:55 | How and why do the Endurant endograft results for EVAR in France differ from the global results: what are the implications<br>Jean-Pierre Becquemin |
| 17:55 – 18:00 | How sac regression at 1 year affects all-cause mortality through 5 year: key insights from the ENGAGE registry<br>Michel Reijnen                    |

We are asking all faculty members to strictly respect the given time limits.